Overview

A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2029-05-01

Target enrollment:

Participant gender:

Summary

The objective of this trial, DBCG R25, will be to evaluate the effect of trastuzumab-deruxtecan versus standard of care on progression-free survival (PFS) in first-line for patients with non-Luminal A, ER-positive/HER2-negative metastatic breast cancer

Phase:

PHASE3

Details

Lead Sponsor:

Danish Breast Cancer Cooperative Group

Treatments:

abemaciclib
ribociclib
trastuzumab deruxtecan